Cargando…

Multi-valent pneumococcal conjugate vaccine for global health: From problem to platform to production

Childhood bacterial meningitis and pneumonia represent leading causes of mortality, with the latter persisting as one of the top causes of mortality for children under 5 y of age. The prohibitive costs of developing and producing broader spectrum conjugate vaccines impact availability and affordabil...

Descripción completa

Detalles Bibliográficos
Autores principales:	Datta, Anup, Kapre, Kapil, Andi-Lolo, Indah, Kapre, Subhash
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2022
Materias:	ISV Annual Congress SF – Article Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9721430/ https://www.ncbi.nlm.nih.gov/pubmed/36239596 http://dx.doi.org/10.1080/21645515.2022.2117949

Ejemplares similares

Building a global immune system
por: Lipkin, W. I., et al.
Publicado: (2022)

Opportunities and challenges for commercializing microarray patches for vaccination from a MAP developer’s perspective
por: Forster, Angus, et al.
Publicado: (2022)

2021 ISV Annual Virtual Congress
por: Cox, Manon
Publicado: (2022)

Meet the fellows: Everything about ISV
por: Doolan, Denise, et al.
Publicado: (2022)

RSV disease in infants and young children: Can we see a brighter future?
por: Baraldi, Eugenio, et al.
Publicado: (2022)

60 Years of viral vaccines
por: Wahren, Britta
Publicado: (2022)

Vaccine manufacturing is essential to ensure access
por: Palomares, Laura A.
Publicado: (2022)

A novel SARS-CoV-2 subunit vaccine engineered on an immune-activating platform technology
por: Quinlan, Edward J., et al.
Publicado: (2022)

Usability, acceptability, and feasibility of a High-Density Microarray Patch (HD-MAP) applicator as a delivery method for vaccination in clinical settings
por: Davies, Cristyn, et al.
Publicado: (2022)

Novel H7N9 influenza immunogen design enhances mobilization of seasonal influenza T cell memory in H3N2 pre-immune mice
por: Moise, Leonard, et al.
Publicado: (2022)

Syringes must be prioritized globally to ensure equitable access to COVID-19 and other essential vaccines and to sustain safe injection practices
por: Fritz, Jenna, et al.
Publicado: (2022)

Development strategy and lessons learned for a 10-valent pneumococcal conjugate vaccine (PNEUMOSIL®)
por: Alderson, Mark R., et al.
Publicado: (2021)

Safety and Immunogenicity of Pneumococcal Conjugate Vaccines in a High-risk Population: A Randomized Controlled Trial of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccine in Papua New Guinean Infants
por: Pomat, William S, et al.
Publicado: (2019)

Technical Development of a New Meningococcal Conjugate Vaccine
por: Frasch, Carl E., et al.
Publicado: (2015)

Multi-dose vials versus single-dose vials for vaccination: perspectives from lower-middle income countries
por: Basu, Saurav, et al.
Publicado: (2022)

Impact of 13-Valent Pneumococcal Conjugate Vaccine on Colonization and Invasive Disease in Cambodian Children
por: Turner, Paul, et al.
Publicado: (2020)

Polyclonal hyper immunoglobulin: A proven treatment and prophylaxis platform for passive immunization to address existing and emerging diseases
por: Tharmalingam, Tharmala, et al.
Publicado: (2021)

From the wild west to the frontiers of immunology: the journey of a Chinese-American scientist
por: Liu, Margaret Ann
Publicado: (2019)

Portrait of an ISV Fellow
por: Palatnik de Sousa, Clarisa Beatriz
Publicado: (2020)

Re-Analysis of Modeling a Switch from a 13-Valent to 10-Valent Pneumococcal Conjugate Vaccine in Canada: Leveraging Real-World Experience from Belgium
por: Wasserman, Matt D., et al.
Publicado: (2018)

Indirect effect of 7-valent and 13-valent pneumococcal conjugated vaccines on pneumococcal pneumonia hospitalizations in elderly
por: Kislaya, Irina, et al.
Publicado: (2019)

Invasive Pneumococcal Disease and 7-Valent Pneumococcal Conjugate Vaccine, the Netherlands
por: van Deursen, Anna M.M., et al.
Publicado: (2012)

Health and economic outcomes of 20-valent pneumococcal conjugate vaccine compared to 15-valent pneumococcal conjugate vaccine strategies for adults in Greece
por: Gourzoulidis, George, et al.
Publicado: (2023)

Immunogenicity, Safety, and Tolerability of 13-Valent Pneumococcal Conjugate Vaccine Followed by 23-Valent Pneumococcal Polysaccharide Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant Aged ≥2 Years: An Open-Label Study
por: Cordonnier, Catherine, et al.
Publicado: (2015)

Impacts of the 13-Valent Pneumococcal Conjugate Vaccine in Children
por: Esposito, Susanna, et al.
Publicado: (2015)

Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease in Greenland
por: Nikolova, Kristiana Alexandrova, et al.
Publicado: (2021)

The impact of introduction of the 10-valent pneumococcal conjugate vaccine on pneumococcal carriage in Nigeria
por: Adamu, Aishatu L., et al.
Publicado: (2023)

Risk Based Decision Algorithms for Management of COVID-19 Associated Rhino-orbital Mucormycosis
por: Gupta, Neeti Kapre, et al.
Publicado: (2021)

Cost-effectiveness of a national immunization program with the 13-valent pneumococcal conjugate vaccine compared with the 10-valent pneumococcal conjugate vaccine in South Korea
por: Kim, Hye-Young, et al.
Publicado: (2020)

Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to the 23-valent pneumococcal polysaccharide vaccine in elderly Japanese adults
por: Shiramoto, Masanari, et al.
Publicado: (2015)

Effectiveness of 7-Valent Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease in HIV-Infected and -Uninfected Children in South Africa: A Matched Case-Control Study
por: Cohen, Cheryl, et al.
Publicado: (2014)

Invasive pneumococcal infection despite 7-valent conjugated vaccine
por: Joye, Sebastien, et al.
Publicado: (2013)

Cost-effectiveness of 13-valent pneumococcal conjugate vaccination in Mongolia
por: Sundaram, Neisha, et al.
Publicado: (2017)

Efficacy and Safety of the Pneumococcal Conjugate-13 Valent Vaccine in Adults
por: Marra, Fawziah, et al.
Publicado: (2019)

Higher valent Pneumococcal Conjugate Vaccines: is it a roller coaster?
por: Oligbu, Godwin
Publicado: (2020)

Decrease in Pneumococcal Co-Colonization following Vaccination with the Seven-Valent Pneumococcal Conjugate Vaccine
por: Valente, Carina, et al.
Publicado: (2012)

Direct Effect of 10-Valent Conjugate Pneumococcal Vaccination on Pneumococcal Carriage in Children Brazil
por: Andrade, Ana Lucia, et al.
Publicado: (2014)

A Review of the Impact of Pneumococcal Polysaccharide Conjugate Vaccine (7-valent) on Pneumococcal Meningitis
por: Tin Tin Htar , Myint, et al.
Publicado: (2013)

1430. Evolving Impact of 13-Valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease
por: Yildirim, Inci, et al.
Publicado: (2018)

Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants
por: Perdrizet, Johnna, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1oijmitqcdnmqhid69r3nop44p